Industry Insights

1. i-Cubed Used End-To-End AI In A Proof-Of-Concept Trial. Here's What They Learned 7/2/2026

   Discover how well AI fared in document generation, patient engagement, data integration, and more in an end-to-end proof-of-concept study run by i-Cubed.

2. Social Media Is Replete With Patient RWD, But How Can Researchers Best Use It? 7/1/2026

   Pistoia Alliance's Thierry Escudier and Aditya Tyagi discuss how social media listening is used in clinical research, how it supports established evidence-generation methods, and how it can become a credible, structured input for drug development.

3. How Translational Biomarker Research Could Change The Trajectory Of Hidradenitis Suppurativa 6/30/2026

   Elisa Maggioli, Ph.D., explains that improving outcomes in HS may depend on moving beyond broad, symptom-based approaches toward more targeted, biologically informed strategies.

4. Why Do Clinical Trials Cost So Much? Looking Beyond The Obvious 6/29/2026

   The true cost of research goes beyond budgets to design, data, and execution inefficiencies. Streamlining processes and early decisions reduces delays, controls costs, and improves study quality.

5. CRF Validation Best Practices: Building Reliable Clinical Trial Databases 6/29/2026

   CRF validation improves data quality and efficiency. Early planning, clear edit checks, and balance reduce rework, ease site burden, and enable more reliable, streamlined study execution.

6. How Protocol Design Decisions Shape Recruitment, Data Quality & Study Startup 6/29/2026

   Protocol design directly affects recruitment, data quality, and startup speed. Clear workflows, streamlined criteria, and early alignment reduce delays, amendments, and improve reliable study execution.

7. Who Is Responsible When AI Helps Write The Consent Form? 6/29/2026

   AI is reshaping consent materials, but accuracy, oversight, and transparency remain essential. As guidance evolves, organizations must balance innovation with accountability to protect participants.

8. Unicycive Therapeutics' Framework For Speedier Clinical Trials 6/29/2026

   Unicycive Therapeutics Vice President of R&D Guru Reddy, Ph.D., shares how his small team moved swiftly through a recent early phase trial.

9. The Lasting Impact Of Treatment Gaps In ARG1-D 6/26/2026

   A patient story from ARG1-D reveals how even brief treatment interruptions can trigger irreversible decline and why continuity of care must remain a priority in rare disease research.

10. Genetic Therapies Bootcamp Highlights From ACMG 2026 Meeting 6/26/2026

    Review of ACMG 2026 Genetic Therapies Bootcamp, including gene therapy, gene editing, ASOs, rare disease trial design, and the evolving role of genetics professionals.